Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma, PMID: 32402160
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC, PMID: 32997907
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer, PMID: 30345906
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial, PMID: 31122901
Pembrolizumab and atezolizumab in triple-negative breast cancer, PMID: 33015734
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial, PMID: 32966830
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial, PMID: 32416780
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial, PMID: 31786121
Atezolizumab for the treatment of breast cancer, PMID: 32067545
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, PMID: 27979383
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial, PMID: 32534646
Atezolizumab for the treatment of triple-negative breast cancer, PMID: 30474425
Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer, PMID: 27903674
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study, PMID: 32502443
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial, PMID: 27939400
Atezolizumab in the treatment of metastatic triple-negative breast cancer, PMID: 32450725
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial, PMID: 33333328
The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer, PMID: 30586539
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial, PMID: 32302702
Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer, PMID: 32248356
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations, PMID: 31829747
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial, PMID: 31079938
Atezolizumab: A Review in Extensive-Stage SCLC, PMID: 32990939
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, PMID: 26952546
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial, PMID: 29268948
IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation, PMID: 32352320
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial, PMID: 31959349
The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer, PMID: 32400223
Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma, PMID: 32888462
Atezolizumab plus Bevacizumab - A Landmark in Liver Cancer, PMID: 32402168
Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC, PMID: 31728860
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial, PMID: 30347025
Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials, PMID: 33166718
Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer, PMID: 31829043
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial, PMID: 33002436
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study, PMID: 30217492
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial, PMID: 31003911
A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis, PMID: 32858235
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab, PMID: 30082870
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study, PMID: 28950298
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients, PMID: 31171876
Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma, PMID: 27981577
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab, PMID: 29080213
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer, PMID: 29777823
Atezolizumab for the treatment of breast cancer, PMID: 29690797
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors, PMID: 30918950
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer, PMID: 30977385
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials, PMID: 32115349
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma, PMID: 27571927
Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer, PMID: 29785577
Clinical insights: atezolizumab-induced myositis mimicking hepatic injury., PMID:40527534
Simultaneous Determination of Atezolizumab and Bevacizumab by LC-MS/MS in Rat Plasma and Its Application to a Pharmacokinetic Study., PMID:40525526
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial., PMID:40523369
Evolving roles of systemic therapy in hepatocellular carcinoma: neoadjuvant and adjuvant strategies., PMID:40518650
Development of Thyrotoxicosis With Positive TSH Receptor Antibody and Transition to Hypothyroidism in a Patient With Unresectable Hepatocellular Carcinoma During Combined Atezolizumab and Bevacizumab Therapy: A Case Report and Review of the Literature., PMID:40518311
Lurbinectedin with atezolizumab maintenance therapy in extensive-stage small-cell lung cancer., PMID:40516996
Advances in targeted therapy for triple-negative breast cancer: a review of key antigens and recent advances., PMID:40515614
Real-World Experiences Using Atezolizumab + Bevacizumab for the Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Study., PMID:40507295
Baseline Radiomics as a Prognostic Tool for Clinical Benefit from Immune Checkpoint Inhibition in Inoperable NSCLC Without Activating Mutations., PMID:40507271
Gender and age disparities in cardiac immune-related adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database., PMID:40506075
Predicting atezolizumab response in metastatic urothelial carcinoma patients using machine learning on integrated tumour gene expression and clinical data., PMID:40494842
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population., PMID:40494131
Implementing performance-based risk-sharing agreements in non-small cell lung cancer immunotherapy: a real-world data case study., PMID:40489036
LMNB2-mediated high PD-L1 transcription triggers the immune escape of hepatocellular carcinoma., PMID:40483310
Validation of a 15-Gene Prognostic Signature in Metastatic Clear Cell Renal Cell Carcinoma., PMID:40479621
Clinical features, treatment, and outcomes of anti-PD-L1 induced psoriasis., PMID:40474015
The current and emerging immunotherapy paradigm in small-cell lung cancer., PMID:40473974
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial., PMID:40473449
Delayed central nervous system progression with atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer (LU23-15)., PMID:40473339
Immune checkpoint inhibitor-induced myocarditis and multiple adverse events with pre-existing rheumatoid arthritis: a case report and literature review., PMID:40471689
Complete Response of Hepatocellular Carcinoma With Inferior Vena Cava Tumor Thrombus and Right Atrium Involvement to Combined Radiotherapy and Immunotherapy: A Case Report., PMID:40470485
Feasibility and outcome of genomics-guided treatment selection in advanced cancer - the MEGALiT explorative clinical trial., PMID:40468525
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial., PMID:40467898
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial., PMID:40467896
Immune-mediated enterocolitis is associated with immune checkpoint inhibitors: A pharmacovigilance study from the FDA Adverse Event Reporting System (FAERS) database., PMID:40465755
Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First-Line Therapy for Intermediate-Stage Hepatocellular Carcinoma Beyond the Up-to-Seven Criteria., PMID:40448543
Treatment of small cell lung cancer; advances and future prospects., PMID:40446464
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial., PMID:40446184
Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers., PMID:40442146
Efficacy and Safety of Lenvatinib versus Atezolizumab Plus Bevacizumab in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis., PMID:40439364
Efficacy and safety of BCG and immune checkpoint inhibitors in non-muscle invasive bladder cancer: A meta-analysis with exploratory chemotherapy comparisons., PMID:40438876
Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma., PMID:40438087
Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab., PMID:40434907
Intrahepatic Lymphoid Follicles Comprising T and B Cells Mimic Hepatocellular Carcinoma in a Hepatitis B Patient., PMID:40429964
Neuroendocrine Neoplasms of the Lungs, Thyroid, and Thymus., PMID:40426858
Which sarcoma requires PD1/PDL1 inhibitors, and what should be the best scheme? Present status and next steps., PMID:40421971
Number of Tumors Stratifies the Therapeutic Response to Atezolizumab Plus Bevacizumab Therapy in Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Multicenter Analysis., PMID:40418927
Immunotherapy in Triple-Negative Breast Cancer., PMID:40418298
The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade., PMID:40416959
Looking Toward the Future: Emerging Therapies for Hepatocellular Carcinoma., PMID:40416920
The Importance of Timing in Immunotherapy: A Systematic Review., PMID:40416194
Adjuvant Immunotherapy in Microsatellite Instability-High Colon Cancer: A Literature Review on Efficacy, Challenges, and Future Directions., PMID:40415356
Subset of Child-Pugh Score 7 Shows Comparable Survival Outcomes to Child-Pugh Score 6 in Hepatocellular Carcinoma Patients Treated with Atezolizumab and Bevacizumab., PMID:40407727
Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer., PMID:40404526
Development and validation of a serum proteomic test for predicting patient outcomes in advanced non-small cell lung cancer treated with atezolizumab or docetaxel., PMID:40404206
Atezolizumab Plus Bevacizumab Combined with or without Transarterial Chemoembolization in the Treatment of Advanced Hepatocellular Carcinoma: A Single-Center Retrospective Study., PMID:40395491
Photoimmuno-Lure Nanoplatform for Enhancing T Cell Expansion in Glioblastoma via Synergistic Treatment of Photodynamic Therapy and Immune Checkpoint Inhibition., PMID:40395101
A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study)., PMID:40391393
Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma., PMID:40387956
Separation of simultaneously acquired [89Zr]atezolizumab and [18F]FDG PET scans., PMID:40387909
For research use only. Not for human or drug use.
